BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy
Background: Utilization of antiepileptic drugs (AEDs) has long been associated with bone deleterious effects. Furthermore, the BsmI restriction fragment polymorphism of the vitamin D receptor (VDR) has been associated with reduced bone mineral density (BMD), mostly in postmenopausal women. This stu...
Gespeichert in:
| Veröffentlicht in: | European journal of neurology 2011-01, Vol.18 (1), p.93-98 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 1 |
| container_start_page | 93 |
| container_title | European journal of neurology |
| container_volume | 18 |
| creator | Lambrinoudaki, I. Kaparos, G. Armeni, E. Alexandrou, A. Damaskos, C. Logothetis, E. Creatsa, M. Antoniou, A. Kouskouni, E. Triantafyllou, N. |
| description | Background: Utilization of antiepileptic drugs (AEDs) has long been associated with bone deleterious effects. Furthermore, the BsmI restriction fragment polymorphism of the vitamin D receptor (VDR) has been associated with reduced bone mineral density (BMD), mostly in postmenopausal women. This study evaluates the association between bone metabolism of patients with epilepsy and the BsmI VDR’s polymorphism in chronic users of AEDs.
Methods: This study evaluated 73 long‐term users of antiepileptic drug monotherapy, in a cross‐sectional design. Fasting blood samples were obtained to estimate the circulating serum levels of calcium, magnesium, phosphorus, parathormone, 25hydroxyvitamin D as well as the VDR’s genotype. Bone mineral density at the lumbar spine was measured with Dual Energy X‐Ray Absorptiometry.
Results: Bone mineral density was significantly associated with the genotype of VDR (mean BMD: Bb genotype 1.056 ± 0.126 g/cm2; BB genotype 1.059 ± 0.113 g/cm2; bb genotype 1.179 ± 0.120 g/cm2; P |
| doi_str_mv | 10.1111/j.1468-1331.2010.03103.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954610344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4107883141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4663-24eef30284386b76b481dea5e215431bb20dc9bc84a288cb739460e144df18123</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhi0EomXhFZAlDj1l8diO4z1woMtSKlUFoSKOlpPMUi9JHOyEbo68OU637IELzMWjme-fkecnhAJbQorXuyVIpTMQApacpSoTwMRy_4icHhuPUy5yyHJgcEKexbhjjPGCs6fkhLOcMc3EKfl1HttL-tMNtnUdfUcDVtgPPpxF2vtman3ob11sqe1qWvoOacIw2IbW2EU3TDSpWuzu-33AlPrejjEBd36u-442vvuWDRjmIYPD3jVpg6vocJsG9dNz8mRrm4gvHt4F-fJ-c7P-kF19vLhcv73KKqmUyLhE3ArGtRRalYUqpYYabY4ccimgLDmrq1VZaWm51lVZiJVUDEHKegsauFiQs8PcPvgfI8bBtC5W2DS2Qz9Gs8qlSkeU8p-kBq0kaKET-eovcufH0KVvGNAMFMtFigXRB6oKPsaAW9MH19owGWBm9tPszGybmW0zs5_m3k-zT9KXDwvGssX6KPxjYALeHIC7dNbpvwebzfVmzpI-O-hdHHB_1Nvw3ahCFLn5en1hzuVnIeTNJ7MWvwFqWr0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1801605333</pqid></control><display><type>article</type><title>BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Lambrinoudaki, I. ; Kaparos, G. ; Armeni, E. ; Alexandrou, A. ; Damaskos, C. ; Logothetis, E. ; Creatsa, M. ; Antoniou, A. ; Kouskouni, E. ; Triantafyllou, N.</creator><creatorcontrib>Lambrinoudaki, I. ; Kaparos, G. ; Armeni, E. ; Alexandrou, A. ; Damaskos, C. ; Logothetis, E. ; Creatsa, M. ; Antoniou, A. ; Kouskouni, E. ; Triantafyllou, N.</creatorcontrib><description>Background: Utilization of antiepileptic drugs (AEDs) has long been associated with bone deleterious effects. Furthermore, the BsmI restriction fragment polymorphism of the vitamin D receptor (VDR) has been associated with reduced bone mineral density (BMD), mostly in postmenopausal women. This study evaluates the association between bone metabolism of patients with epilepsy and the BsmI VDR’s polymorphism in chronic users of AEDs.
Methods: This study evaluated 73 long‐term users of antiepileptic drug monotherapy, in a cross‐sectional design. Fasting blood samples were obtained to estimate the circulating serum levels of calcium, magnesium, phosphorus, parathormone, 25hydroxyvitamin D as well as the VDR’s genotype. Bone mineral density at the lumbar spine was measured with Dual Energy X‐Ray Absorptiometry.
Results: Bone mineral density was significantly associated with the genotype of VDR (mean BMD: Bb genotype 1.056 ± 0.126 g/cm2; BB genotype 1.059 ± 0.113 g/cm2; bb genotype 1.179 ± 0.120 g/cm2; P < 0.05). Additionally, the presence of at least one B allele was significantly associated with lower bone mineral density (B allele present: BMD = 1.057 ± 0.12 g/cm2, B allele absent: BMD = 1.179 ± 0.119 g/cm2; P < 0.01). Patients with at least one B allele had lower serum levels of 25hydroxyvitamin D when compared with bb patients (22.61 ng/ml vs. 33.27 ng/ml, P < 0.05), whilst they tended to have higher levels of parathyroid hormone.
Discussion: Vitamin D receptor polymorphism is associated with lower bone mass in patients with epilepsy. This effect might be mediated through the vitamin D‐parathormone pathway.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/j.1468-1331.2010.03103.x</identifier><identifier>PMID: 20500803</identifier><identifier>CODEN: EJNEFL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Absorptiometry, Photon ; Adolescent ; Adult ; Alleles ; Anticonvulsants - therapeutic use ; Bone Density - genetics ; bone mineral density ; BsmI ; Calcium, Dietary ; Carbamazepine - analogs & derivatives ; Carbamazepine - therapeutic use ; Cross-Sectional Studies ; epilepsy ; Epilepsy - drug therapy ; Epilepsy - genetics ; Female ; Genotype ; Humans ; Indexing in process ; Male ; Middle Aged ; Piracetam - analogs & derivatives ; Piracetam - therapeutic use ; Polymorphism, Genetic ; Premenopause - genetics ; Receptors, Calcitriol - genetics ; Regression Analysis ; Statistics, Nonparametric ; Valproic Acid - therapeutic use ; VDR</subject><ispartof>European journal of neurology, 2011-01, Vol.18 (1), p.93-98</ispartof><rights>2010 The Author(s). European Journal of Neurology © 2010 EFNS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4663-24eef30284386b76b481dea5e215431bb20dc9bc84a288cb739460e144df18123</citedby><cites>FETCH-LOGICAL-c4663-24eef30284386b76b481dea5e215431bb20dc9bc84a288cb739460e144df18123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1468-1331.2010.03103.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1468-1331.2010.03103.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20500803$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lambrinoudaki, I.</creatorcontrib><creatorcontrib>Kaparos, G.</creatorcontrib><creatorcontrib>Armeni, E.</creatorcontrib><creatorcontrib>Alexandrou, A.</creatorcontrib><creatorcontrib>Damaskos, C.</creatorcontrib><creatorcontrib>Logothetis, E.</creatorcontrib><creatorcontrib>Creatsa, M.</creatorcontrib><creatorcontrib>Antoniou, A.</creatorcontrib><creatorcontrib>Kouskouni, E.</creatorcontrib><creatorcontrib>Triantafyllou, N.</creatorcontrib><title>BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background: Utilization of antiepileptic drugs (AEDs) has long been associated with bone deleterious effects. Furthermore, the BsmI restriction fragment polymorphism of the vitamin D receptor (VDR) has been associated with reduced bone mineral density (BMD), mostly in postmenopausal women. This study evaluates the association between bone metabolism of patients with epilepsy and the BsmI VDR’s polymorphism in chronic users of AEDs.
Methods: This study evaluated 73 long‐term users of antiepileptic drug monotherapy, in a cross‐sectional design. Fasting blood samples were obtained to estimate the circulating serum levels of calcium, magnesium, phosphorus, parathormone, 25hydroxyvitamin D as well as the VDR’s genotype. Bone mineral density at the lumbar spine was measured with Dual Energy X‐Ray Absorptiometry.
Results: Bone mineral density was significantly associated with the genotype of VDR (mean BMD: Bb genotype 1.056 ± 0.126 g/cm2; BB genotype 1.059 ± 0.113 g/cm2; bb genotype 1.179 ± 0.120 g/cm2; P < 0.05). Additionally, the presence of at least one B allele was significantly associated with lower bone mineral density (B allele present: BMD = 1.057 ± 0.12 g/cm2, B allele absent: BMD = 1.179 ± 0.119 g/cm2; P < 0.01). Patients with at least one B allele had lower serum levels of 25hydroxyvitamin D when compared with bb patients (22.61 ng/ml vs. 33.27 ng/ml, P < 0.05), whilst they tended to have higher levels of parathyroid hormone.
Discussion: Vitamin D receptor polymorphism is associated with lower bone mass in patients with epilepsy. This effect might be mediated through the vitamin D‐parathormone pathway.</description><subject>Absorptiometry, Photon</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Alleles</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Bone Density - genetics</subject><subject>bone mineral density</subject><subject>BsmI</subject><subject>Calcium, Dietary</subject><subject>Carbamazepine - analogs & derivatives</subject><subject>Carbamazepine - therapeutic use</subject><subject>Cross-Sectional Studies</subject><subject>epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy - genetics</subject><subject>Female</subject><subject>Genotype</subject><subject>Humans</subject><subject>Indexing in process</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piracetam - analogs & derivatives</subject><subject>Piracetam - therapeutic use</subject><subject>Polymorphism, Genetic</subject><subject>Premenopause - genetics</subject><subject>Receptors, Calcitriol - genetics</subject><subject>Regression Analysis</subject><subject>Statistics, Nonparametric</subject><subject>Valproic Acid - therapeutic use</subject><subject>VDR</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhi0EomXhFZAlDj1l8diO4z1woMtSKlUFoSKOlpPMUi9JHOyEbo68OU637IELzMWjme-fkecnhAJbQorXuyVIpTMQApacpSoTwMRy_4icHhuPUy5yyHJgcEKexbhjjPGCs6fkhLOcMc3EKfl1HttL-tMNtnUdfUcDVtgPPpxF2vtman3ob11sqe1qWvoOacIw2IbW2EU3TDSpWuzu-33AlPrejjEBd36u-442vvuWDRjmIYPD3jVpg6vocJsG9dNz8mRrm4gvHt4F-fJ-c7P-kF19vLhcv73KKqmUyLhE3ArGtRRalYUqpYYabY4ccimgLDmrq1VZaWm51lVZiJVUDEHKegsauFiQs8PcPvgfI8bBtC5W2DS2Qz9Gs8qlSkeU8p-kBq0kaKET-eovcufH0KVvGNAMFMtFigXRB6oKPsaAW9MH19owGWBm9tPszGybmW0zs5_m3k-zT9KXDwvGssX6KPxjYALeHIC7dNbpvwebzfVmzpI-O-hdHHB_1Nvw3ahCFLn5en1hzuVnIeTNJ7MWvwFqWr0g</recordid><startdate>201101</startdate><enddate>201101</enddate><creator>Lambrinoudaki, I.</creator><creator>Kaparos, G.</creator><creator>Armeni, E.</creator><creator>Alexandrou, A.</creator><creator>Damaskos, C.</creator><creator>Logothetis, E.</creator><creator>Creatsa, M.</creator><creator>Antoniou, A.</creator><creator>Kouskouni, E.</creator><creator>Triantafyllou, N.</creator><general>Blackwell Publishing Ltd</general><general>John Wiley & Sons, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201101</creationdate><title>BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy</title><author>Lambrinoudaki, I. ; Kaparos, G. ; Armeni, E. ; Alexandrou, A. ; Damaskos, C. ; Logothetis, E. ; Creatsa, M. ; Antoniou, A. ; Kouskouni, E. ; Triantafyllou, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4663-24eef30284386b76b481dea5e215431bb20dc9bc84a288cb739460e144df18123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Absorptiometry, Photon</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Alleles</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Bone Density - genetics</topic><topic>bone mineral density</topic><topic>BsmI</topic><topic>Calcium, Dietary</topic><topic>Carbamazepine - analogs & derivatives</topic><topic>Carbamazepine - therapeutic use</topic><topic>Cross-Sectional Studies</topic><topic>epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy - genetics</topic><topic>Female</topic><topic>Genotype</topic><topic>Humans</topic><topic>Indexing in process</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piracetam - analogs & derivatives</topic><topic>Piracetam - therapeutic use</topic><topic>Polymorphism, Genetic</topic><topic>Premenopause - genetics</topic><topic>Receptors, Calcitriol - genetics</topic><topic>Regression Analysis</topic><topic>Statistics, Nonparametric</topic><topic>Valproic Acid - therapeutic use</topic><topic>VDR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lambrinoudaki, I.</creatorcontrib><creatorcontrib>Kaparos, G.</creatorcontrib><creatorcontrib>Armeni, E.</creatorcontrib><creatorcontrib>Alexandrou, A.</creatorcontrib><creatorcontrib>Damaskos, C.</creatorcontrib><creatorcontrib>Logothetis, E.</creatorcontrib><creatorcontrib>Creatsa, M.</creatorcontrib><creatorcontrib>Antoniou, A.</creatorcontrib><creatorcontrib>Kouskouni, E.</creatorcontrib><creatorcontrib>Triantafyllou, N.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lambrinoudaki, I.</au><au>Kaparos, G.</au><au>Armeni, E.</au><au>Alexandrou, A.</au><au>Damaskos, C.</au><au>Logothetis, E.</au><au>Creatsa, M.</au><au>Antoniou, A.</au><au>Kouskouni, E.</au><au>Triantafyllou, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2011-01</date><risdate>2011</risdate><volume>18</volume><issue>1</issue><spage>93</spage><epage>98</epage><pages>93-98</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><coden>EJNEFL</coden><abstract>Background: Utilization of antiepileptic drugs (AEDs) has long been associated with bone deleterious effects. Furthermore, the BsmI restriction fragment polymorphism of the vitamin D receptor (VDR) has been associated with reduced bone mineral density (BMD), mostly in postmenopausal women. This study evaluates the association between bone metabolism of patients with epilepsy and the BsmI VDR’s polymorphism in chronic users of AEDs.
Methods: This study evaluated 73 long‐term users of antiepileptic drug monotherapy, in a cross‐sectional design. Fasting blood samples were obtained to estimate the circulating serum levels of calcium, magnesium, phosphorus, parathormone, 25hydroxyvitamin D as well as the VDR’s genotype. Bone mineral density at the lumbar spine was measured with Dual Energy X‐Ray Absorptiometry.
Results: Bone mineral density was significantly associated with the genotype of VDR (mean BMD: Bb genotype 1.056 ± 0.126 g/cm2; BB genotype 1.059 ± 0.113 g/cm2; bb genotype 1.179 ± 0.120 g/cm2; P < 0.05). Additionally, the presence of at least one B allele was significantly associated with lower bone mineral density (B allele present: BMD = 1.057 ± 0.12 g/cm2, B allele absent: BMD = 1.179 ± 0.119 g/cm2; P < 0.01). Patients with at least one B allele had lower serum levels of 25hydroxyvitamin D when compared with bb patients (22.61 ng/ml vs. 33.27 ng/ml, P < 0.05), whilst they tended to have higher levels of parathyroid hormone.
Discussion: Vitamin D receptor polymorphism is associated with lower bone mass in patients with epilepsy. This effect might be mediated through the vitamin D‐parathormone pathway.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20500803</pmid><doi>10.1111/j.1468-1331.2010.03103.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-5101 |
| ispartof | European journal of neurology, 2011-01, Vol.18 (1), p.93-98 |
| issn | 1351-5101 1468-1331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_954610344 |
| source | MEDLINE; Wiley Journals |
| subjects | Absorptiometry, Photon Adolescent Adult Alleles Anticonvulsants - therapeutic use Bone Density - genetics bone mineral density BsmI Calcium, Dietary Carbamazepine - analogs & derivatives Carbamazepine - therapeutic use Cross-Sectional Studies epilepsy Epilepsy - drug therapy Epilepsy - genetics Female Genotype Humans Indexing in process Male Middle Aged Piracetam - analogs & derivatives Piracetam - therapeutic use Polymorphism, Genetic Premenopause - genetics Receptors, Calcitriol - genetics Regression Analysis Statistics, Nonparametric Valproic Acid - therapeutic use VDR |
| title | BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A59%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BsmI%20vitamin%20D%20receptor's%20polymorphism%20and%20bone%20mineral%20density%20in%20men%20and%20premenopausal%20women%20on%20long-term%20antiepileptic%20therapy&rft.jtitle=European%20journal%20of%20neurology&rft.au=Lambrinoudaki,%20I.&rft.date=2011-01&rft.volume=18&rft.issue=1&rft.spage=93&rft.epage=98&rft.pages=93-98&rft.issn=1351-5101&rft.eissn=1468-1331&rft.coden=EJNEFL&rft_id=info:doi/10.1111/j.1468-1331.2010.03103.x&rft_dat=%3Cproquest_cross%3E4107883141%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1801605333&rft_id=info:pmid/20500803&rfr_iscdi=true |